The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden

• Published in: Diabetes therapy Vol. 12; no. 11; pp. 2977 - 2991
• Main Authors: Jendle, Johan, Buompensiere, M. I., Holm, A. L., de Portu, S., Malkin, S. J. P., Cohen, O.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-11-2021; Springer; Springer Nature B.V
• Subjects: Advanced hybrid closed-loop; Cardiology; Care and treatment; Cost analysis; Cost control; Cost-effectiveness; Diabetes; Economic analysis; Endocrinology; Glucose monitors; Hypoglycemia; Innovations; Insulin; Internal Medicine; Life expectancy; Medicine; Medicine & Public Health; Observational studies; Original Research; Sweden; Type 1 diabetes; Sweden; Sweden; Advanced hybrid closed-loop; Type 1 diabetes; Cost-effectiveness
• ISSN: 1869-6953; 1869-6961; 1869-6961
• DOI: 10.1007/s13300-021-01157-0

Introduction
Swedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25 years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden.
Methods
Outcomes were projected over patients’ lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources.
Results
The MiniMed 780G system was associated with an improvement in life expectancy of 0.16 years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR 72,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK 373,700 per QALY gained.
Conclusions
Based on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.